In type 2 diabetes, SGLT2 inhibitors reduce all-cause, but not cardiovascular, mortality vs. GLP-1 RAs.
meta_analysis · Level I
Where this comes from
- Record sourced from PubMed, PMID 34058114.
- Also identified by DOI 10.7326/ACPJ202106150-067.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Palmer SC, Tendal B, Mustafa RA, et al. <b>Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials.</b> BMJ. 2021;372:m4573. 33441402.
Medical subject headings
- Diabetes Mellitus, Type 2
- Sodium-Glucose Transporter 2 Inhibitors